Novartis tries to rescue stalled inclisiran filing with FDANovartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on Share XNovartis tries to rescue stalled inclisiran filing with FDAhttps://pharmaphorum.com/news/novartis-tries-to-rescue-stalled-inclisiran-filing-with-fda/
FDA rejects Novartis’ cholesterol drug after factory inspection issueNovartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster Share XFDA rejects Novartis’ cholesterol drug after factory inspection issuehttps://pharmaphorum.com/news/fda-rejects-novartis-cholesterol-drug-after-missed-factory-inspection/
Novartis’ big bet on inclisiran nears fruition, as CHMP backs drugNovartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering Share XNovartis’ big bet on inclisiran nears fruition, as CHMP backs drughttps://pharmaphorum.com/news/novartis-big-bet-on-inclisiran-nears-fruition-as-chmp-backs-drug/
Novartis plots cardio trial in UK as London HQ opensNovartis has announced the beginnings of a major cardiovascular outcomes trial in the UK, as it opened a Share XNovartis plots cardio trial in UK as London HQ openshttps://pharmaphorum.com/news/novartis-plots-cardio-trial-in-uk-as-london-hq-opens/
Novartis strikes landmark deal with NHS to speed up inclisiran accessNovartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran Share XNovartis strikes landmark deal with NHS to speed up inclisiran accesshttps://pharmaphorum.com/news/novartis-strikes-landmark-deal-with-nhs-to-speed-up-inclisiran-access/
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering Share XTMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/
TMC inches closer to inclisiran approval with long-term safety dataThe Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety Share XTMC inches closer to inclisiran approval with long-term safety datahttps://pharmaphorum.com/news/tmc-inches-closer-to-inclisiran-approval-with-long-term-safety-data/
